Date: 2014-09-15
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Boehringer Ingelheim (Germany)
Product: BI 409306
Action
mechanism: phosphodiesterase inhibitor/phosphodiesterase 9A inhibitor/PDE inhibitor. BI 409306 is an inhibitor of phosphodisterase 9A. PDE9A is a drug target for cognitive decline in Alzheimer's and other diseases because this enzyme reduces brain levels of the second messenger cyclic guanosine monophosphate. cGMP transduces signals by the neurotransmitters nitric oxide and glutamate. This pathway modulates synaptic transmission and plasticity in the hippocampus and cerebral cortex, and is reduced in AD brain (Zhihui 2013).
Disease: Alzheimer's disease
Therapeutic area: Neurodegenerative diseases
Country: Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, UK, USA
Trial
details: The study is designed to compare the effects of 4 different doses of orally administered BI 409306 to placebo in patients with Alzheimers Disease. (NCT02240693 )
Latest
news: * On September 15, 2014, a Phase 2 trial sponsored by Boehringer Ingelheim was published on the NIH website ClinicalTrials.gov for BI 409306 and is currently recruiting participants.
